AZQ

AZQ

diaziquone.
Mentioned in ?
References in periodicals archive ?
The increase was due to higher personnel expenses, higher expenditures related to the company's Phase III clinical trials in Ethyol and NeuTrexin, increased product development expenditures for drug products FddA and AZQ and initial user fees payable to the FDA related to the company's manufacturing facility in The Netherlands.
The current focus on the development pipeline is AZQ, a treatment for advanced gliomas (brain tumors) and F-ddA, a new anti-HIV therapy in clinical testing at the National Institutes of Health.
The company maintains a strong development pipeline, with the current focus on AZQ for gliomas and F-ddA for the management of HIV.